Hyperion Therapeutics to Present at the

Error. Page cannot be displayed. Please contact your service provider for more details. (14)

32nd Annual J.P. Morgan Healthcare Conference
Print
GlobeNewswire
Wednesday, 08 January 2014 10:05

SOUTH SAN FRANCISCO, Calif.--Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the 32nd Annual J.P. Morgan Healthcare Conference on Thursday, January 16 at 7:30 a.m. PT.

Donald J. Santel, chief executive officer, will provide a company overview. To access the live webcast and subsequent archived recording, please visit Hyperion's website at http://investors.hyperiontx.com/events.cfm.

About Hyperion Therapeutics

Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases and hepatology. The company's first commercial product, RAVICTI® (glycerol phenylbutyrate) Oral Liquid, was approved in February 2013 and is currently being marketed in the United States. The company also owns worldwide rights to BUPHENYL® (sodium phenylbutyrate) Tablets and Powder, which it markets in the U.S. The compound is also marketed internationally through business partners. For more information, please visit www.hyperiontx.com.

CONTACT: Sylvia Wheeler, Investor Relations          (650) 745-7834          sylvia.wheeler@hyperiontx.com



BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and
firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
  BMR:1